DarioHealth Corp. Stock

Equities

DRIO

US23725P2092

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-04-25 pm EDT 5-day change 1st Jan Change
1.47 USD -2.00% Intraday chart for DarioHealth Corp. +27.83% -14.53%
Sales 2024 * 37.33M Sales 2025 * 49.7M Capitalization 43.62M
Net income 2024 * -61M Net income 2025 * -42M EV / Sales 2024 * 1.17 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.88 x
P/E ratio 2024 *
-0.86 x
P/E ratio 2025 *
-1.04 x
Employees 285
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.19%
More Fundamentals * Assessed data
Dynamic Chart
DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes CI
DarioHealth Corp. Signs Two Employers for Cardiometabolic Suite with Integrated Glp-1 Solution CI
DarioHealth Corp. Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health CI
Two National Employers Select DarioHealth Corp.'S Integrated Chronic Condition Solution to Improve Employee Health CI
Transcript : DarioHealth Corp., 2023 Earnings Call, Mar 28, 2024
DarioHealth Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Set for -2- DJ
North American Morning Briefing : Investors -2- DJ
DarioHealth Corp. Announces Two New Clinical Studies Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024 CI
Transcript : DarioHealth Corp., Twill, Inc. - M&A Call
DarioHealth Corp. Appoints Tomer Ben-Kiki as Chief Operating Officer CI
DarioHealth Corp. announced that it has received $22.422 million in funding CI
DarioHealth Corp. acquired Twill, Inc. for $34.4 million. CI
DarioHealth Corp. announced that it expects to receive $22.422 million in funding CI
DarioHealth to Provide Diabetes, Weight-Control Services for Food Services Union Members MT
More news
1 day-2.00%
1 week+27.83%
Current month-3.92%
1 month-1.34%
3 months-29.33%
6 months-3.92%
Current year-14.53%
More quotes
1 week
1.18
Extreme 1.175
1.52
1 month
1.05
Extreme 1.0501
1.66
Current year
1.05
Extreme 1.0501
2.60
1 year
0.68
Extreme 0.68
4.58
3 years
0.68
Extreme 0.68
23.80
5 years
0.68
Extreme 0.68
31.85
10 years
0.68
Extreme 0.68
3 258.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 12-09-30
Founder - 11-08-10
Director of Finance/CFO 63 15-01-06
Members of the board TitleAgeSince
Director/Board Member 67 13-11-11
Director/Board Member 60 11-10-26
Chairman 52 18-07-04
More insiders
Date Price Change Volume
24-04-25 1.47 -2.00% 44,645
24-04-24 1.5 +3.45% 40,413
24-04-23 1.45 +9.85% 166,572
24-04-22 1.32 +13.79% 179,404
24-04-19 1.16 +0.87% 50,464

Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT

More quotes
DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.47 USD
Average target price
5.667 USD
Spread / Average Target
+285.49%
Consensus